

Yes, Wegovy and Ozempic share the same active ingredient, semaglutide. But Wegovy was purpose-built for weight loss at more than double the dose, tested in its own dedicated clinical trial programme, and approved specifically for weight management. They are different tools for different jobs.
For anyone searching for Wegovy in Singapore, this distinction matters. The STEP trial programme studied semaglutide at 2.4 mg weekly -- the Wegovy dose -- and the results were striking. Participants lost an average of 14.9% of their body weight, with nearly a third losing more than 20%.
This guide covers what Wegovy actually is, the clinical evidence behind it, who qualifies in Singapore, how dosing works, what side effects to expect, what it costs, and how to get started.
Wegovy is a brand-name medication manufactured by Novo Nordisk containing semaglutide at a dose of 2.4 mg per week. It is the first semaglutide product specifically developed and approved for chronic weight management in adults.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces after eating to signal fullness and regulate blood sugar. Wegovy mimics this hormone, but in a form that is far more potent and longer-lasting than what your body produces on its own.
Wegovy acts on multiple systems at once:
The net effect is that your brain receives clearer, stronger signals that you have had enough to eat. Patients often describe this as the biggest change: not white-knuckling through cravings, but actually feeling less interested in overeating.
Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen, typically in the abdomen, thigh, or upper arm. For a broader overview of all GLP-1 treatment options, see your guide to weight loss medication.
This is the question that comes up most often: if Wegovy and Ozempic are both semaglutide, why does it matter which one you take?
The short answer: dose and indication.
| Feature | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Approved indication | Chronic weight management | Type 2 diabetes |
| Maximum dose | 2.4 mg weekly | 1 mg weekly |
| Administration | Weekly injection | Weekly injection |
| Dose escalation | 5 steps over 16 weeks | 3 steps over 8 weeks |
Ozempic was developed for blood sugar control in people with Type 2 diabetes. Its maximum dose is 1 mg weekly. Doctors frequently prescribe it off-label for weight loss because the same mechanism that manages blood sugar also reduces appetite. But at 1 mg, patients typically lose less weight than the headline STEP trial figures suggest, since those trials were all conducted at the 2.4 mg Wegovy dose.
Wegovy was designed from the start with weight management as the primary goal. Its five-step titration schedule takes you to 2.4 mg over 16 to 20 weeks, and the clinical trials specifically measured weight loss outcomes in people without diabetes.
Whether your doctor recommends Wegovy or Ozempic depends on your health profile, availability, and treatment goals. For a detailed look at the Ozempic side of this comparison, read our Ozempic Singapore guide.
Wegovy's weight loss effects are not based on anecdotes or small studies. They come from the STEP trial programme (Semaglutide Treatment Effect in People with obesity), a large-scale clinical trial series for obesity treatment involving thousands of participants across multiple countries.
| Trial | Population | Mean weight loss | Duration | Source |
|---|---|---|---|---|
| STEP 1 | Overweight/obesity, no diabetes | 14.9% | 68 weeks | Wilding et al., NEJM 2021 |
| STEP 2 | Overweight/obesity + Type 2 diabetes | 9.6% | 68 weeks | Davies et al., Lancet 2021 |
| STEP 3 | Obesity + intensive behavioural therapy | 16.0% | 68 weeks | Wadden et al., JAMA 2021 |
| STEP 4 | Continued treatment vs withdrawal | 17.4% (continued) | 68 weeks | Rubino et al., JAMA 2021 |
| STEP 5 | Long-term maintenance | 15.2% | 104 weeks | Garvey et al., Nat Med 2022 |
| STEP 8 | Semaglutide vs liraglutide (head-to-head) | 15.8% | 68 weeks | Rubino et al., JAMA 2022 |
The landmark STEP 1 trial gives the clearest picture for people without diabetes:
For someone weighing 85 kg, a 15% weight loss translates to roughly 12.7 kg. That is enough to meaningfully improve blood pressure, blood sugar levels, cholesterol, joint pain, and overall quality of life. Losing 5-10% of body weight is the threshold where doctors begin to see measurable improvements in metabolic health markers.
The STEP 5 trial is particularly worth noting because it tracked outcomes for two full years. At 104 weeks, participants maintained an average weight loss of 15.2%, showing that the effects can be sustained with ongoing treatment. For more on the long-term picture, read about GLP-1 medications for long-term weight loss.
Wegovy's regulatory status in Singapore differs from some other markets. Currently, semaglutide is available through licensed clinics and telehealth providers.
In Singapore, doctors can prescribe semaglutide for weight management based on clinical guidelines and their professional judgement. Whether your prescription is filled as Wegovy (2.4 mg for weight management) or Ozempic (up to 1 mg, off-label for weight loss) depends on what your doctor determines is most appropriate for your situation, along with current medication availability.
The key requirement is that semaglutide must be prescribed by a registered doctor following a proper medical evaluation. You cannot purchase it over the counter, and buying from unverified overseas sources carries serious risks, including counterfeit medication without quality assurance.
Through a licensed telehealth clinic, you can access a consultation and receive your medication without visiting a physical clinic. Trimly is a MOH-licensed telehealth provider that focuses exclusively on GLP-1 weight loss treatment.
Not everyone is a candidate for Wegovy or other GLP-1 medications. Eligibility depends on BMI, overall health, and specific medical criteria.
The Ministry of Health guidelines recommend pharmacotherapy for weight management when:
These thresholds are already lower than Western guidelines because Asian populations face elevated metabolic risks at lower BMIs.
At Trimly, our doctors can prescribe GLP-1 medications for patients meeting the following criteria:
To put those numbers in context, for a woman who is 160 cm tall:
- BMI 24 is approximately 61 kg
- BMI 27.5 is approximately 70 kg
Wegovy is contraindicated in the following situations:
Your doctor will review your full medical history during the consultation to determine whether Wegovy is safe and appropriate for you. Learn more about what doctors check before prescribing GLP-1 treatment.
Wegovy follows a gradual dose escalation over 16 to 20 weeks. This slow titration is deliberate. It gives your body time to adjust and significantly reduces the likelihood of side effects.
| Period | Weekly dose | Purpose |
|---|---|---|
| Weeks 1-4 | 0.25 mg | Tolerability -- lets your GI system adjust |
| Weeks 5-8 | 0.5 mg | Building tolerance |
| Weeks 9-12 | 1.0 mg | Therapeutic effects begin |
| Weeks 13-16 | 1.7 mg | Approaching maintenance |
| Week 17 onwards | 2.4 mg | Full maintenance dose |
Some patients may stay at a lower dose if they are responding well and tolerating it without difficulty. Others may need a slower titration if side effects are pronounced at a particular step. Your doctor will adjust the schedule based on how you respond.
Like all medications, Wegovy can cause side effects. Most are well-characterised, typically mild, and tend to improve as your body adjusts.
The most frequently reported effects are gastrointestinal and usually peak during dose escalation:
These strategies help most patients through the adjustment period:
Most patients find that side effects improve significantly after the first four to six weeks. The gradual dose escalation is specifically designed to minimise these effects.
While uncommon, seek medical attention promptly if you experience:
At Trimly, every patient has access to unlimited follow-up consultations and responsive doctor support via WhatsApp, so you are never managing side effects alone.
Cost is a practical concern for anyone considering GLP-1 treatment, and it is worth being upfront about what to expect.
| Cost component | Typical range |
|---|---|
| GLP-1 medication | $400-$700/month |
| Doctor consultation | $50-$150 per visit |
| Follow-up visits | $50-$100 each |
| Blood tests (if required) | $50-$200 |
| Total monthly cost | $500-$900+ |
Many clinics charge separately for consultations, medication, follow-ups, and monitoring, which makes the total cost unpredictable.
At Trimly, everything is bundled:
The exact price depends on the specific medication and dose your doctor prescribes. You will know the full cost before starting treatment.
For a detailed comparison across all providers and GLP-1 medications, read our guide on GLP-1 treatment costs in Singapore.
Generally, no. GLP-1 medications prescribed for weight loss are typically not covered by Medisave or standard health insurance in Singapore. The exception: if semaglutide is prescribed for its approved diabetes indication and you have a BMI of 27.5 or above, partial coverage may be possible. Coverage rules are evolving, so check with your insurer.
Ready to find out if Wegovy is right for you?
Book Consultation
Wegovy is a prescription-only medication, which means you need a proper medical evaluation before starting. Through Trimly, the process can be completed from home:
The process from initial questionnaire to receiving your medication can happen within days. There is no need to take time off work or arrange childcare for clinic visits.
Trimly is an MOH-licensed clinic (HCSA Licence R/25M0505/MDS/001/252) focused exclusively on GLP-1 weight loss treatment. Our doctors do not prescribe GLP-1 as a sideline. It is all they do.
Most patients notice reduced appetite and quieter food noise within the first one to two weeks. Visible weight loss typically becomes apparent within four to eight weeks as you titrate to higher doses. The STEP trials measured outcomes at 68 weeks (about 16 months), and weight loss tends to be gradual and steady rather than sudden. The most noticeable changes usually occur between months three and nine.
Semaglutide is available through licensed clinics and telehealth providers in Singapore. Your doctor will determine the most appropriate semaglutide formulation and dose for your situation. Access through a licensed provider ensures you receive genuine medication with proper medical supervision.
Research from the STEP 4 trial (Rubino et al., JAMA, 2021) found that patients who switched from semaglutide to placebo regained approximately two-thirds of the weight they had lost within a year. This is why building sustainable lifestyle habits alongside medication matters. Your doctor will work with you on a long-term strategy, including habits that support lasting results.
PCOS may actually make you a strong candidate for GLP-1 treatment. The condition is linked to insulin resistance and hormonal imbalances that make weight loss harder through conventional approaches. GLP-1 medications address the metabolic factors that contribute to weight gain with PCOS. Your doctor will evaluate your specific situation during the consultation.
They contain the same active ingredient, but Wegovy's higher dose (2.4 mg vs 1 mg) generally produces more weight loss. The STEP trial data showing approximately 15% weight loss was all generated at the 2.4 mg dose. At Ozempic's 1 mg dose, results are typically more moderate. Your doctor will help determine which formulation and dose is right for your goals.
Wegovy is not a replacement for healthy habits. It works best as part of a broader approach that includes sensible eating and regular physical activity. That said, the medication makes those changes easier by reducing hunger and food noise. You are not fighting your biology on top of making lifestyle changes. The STEP 3 trial, which combined semaglutide with intensive behavioural therapy, showed the highest weight loss at 16.0%.
Medical disclaimer: Individual results vary. The weight loss figures cited in this article are from clinical trials with specific populations and protocols. Your results will depend on your individual health profile, adherence to treatment, and lifestyle factors. Always discuss expected outcomes with your prescribing doctor.
The clinical evidence for Wegovy is strong: sustained weight loss of approximately 15% over 68 weeks, maintained for at least two years in longer-term studies. And for many patients, the reduction in hunger and food noise is what makes the real difference day to day.
Here is what matters most:
If you have been working hard at weight loss without lasting results, your biology may have been working against you. GLP-1 treatment addresses the hormonal drivers of hunger that calorie counting alone cannot override. A conversation with a doctor is the first step in understanding whether it is right for you.
Ready to find out if Wegovy is right for you?
Book Consultation